Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies

[1]  F. Martinez,et al.  Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk , 2018, American journal of respiratory and critical care medicine.

[2]  D. Cohen,et al.  Publisher's Note , 2017, Neuroscience & Biobehavioral Reviews.

[3]  H. Watz,et al.  Chronic obstructive pulmonary disease , 2017, The Lancet.

[4]  G. Feldman,et al.  Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study , 2016, International journal of chronic obstructive pulmonary disease.

[5]  E. Kerwin,et al.  Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study. , 2016, Chronic obstructive pulmonary diseases.

[6]  K. Verhamme,et al.  Cardiac effects of current treatments of chronic obstructive pulmonary disease. , 2016, The Lancet. Respiratory medicine.

[7]  B. Dautzenberg,et al.  Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit , 2015, European Respiratory Journal.

[8]  Dirkje S Postma,et al.  Risk factors and early origins of chronic obstructive pulmonary disease , 2015, The Lancet.

[9]  W. Aronow,et al.  Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use , 2014, Expert opinion on drug safety.

[10]  D. Mannino,et al.  Epidemiology and prevalence of chronic obstructive pulmonary disease. , 2014, Clinics in chest medicine.

[11]  S. Kon,et al.  Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. , 2014, The Lancet. Respiratory medicine.

[12]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[13]  S. Hurd,et al.  The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD) – why and what? , 2012, The clinical respiratory journal.

[14]  N. Hanania,et al.  The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications. , 2012, Respiratory medicine.

[15]  N. Thomson,et al.  Impact of Smoking on Asthma Therapy , 2012, Drugs.

[16]  N. Benowitz.  Nicotine addiction. , 2010, The New England journal of medicine.

[17]  M. Decramer,et al.  Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial , 2009, European Respiratory Journal.

[18]  P. Calverley,et al.  Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. , 2008, American journal of respiratory and critical care medicine.

[19]  M. Decramer,et al.  Bronchodilator responsiveness in patients with COPD , 2008, European Respiratory Journal.

[20]  N. Thomson,et al.  Review: Treating patients with respiratory disease who smoke , 2008, Therapeutic advances in respiratory disease.

[21]  J. Moita,et al.  Tiotropium improves FEV1 in patients with COPD irrespective of smoking status. , 2008, Pulmonary pharmacology & therapeutics.

[22]  E. Israel,et al.  Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. , 2007, American journal of respiratory and critical care medicine.

[23]  D. Górecka,et al.  Differences in responses upon corticosteroid therapy between smoking and non-smoking patients with COPD. , 2006, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[24]  D. Mahler,et al.  The MCID of the Transition Dyspnea Index is a Total Score of One Unit , 2005, COPD.

[25]  P. Jones.  St. George's Respiratory Questionnaire: MCID , 2005, COPD.

[26]  S. Hurd,et al.  Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update , 2003, European Respiratory Journal.

[27]  K Larsson,et al.  Not 15 but 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern Sweden Studies. , 2003, Respiratory medicine.

[28]  K. J. Macleod,et al.  Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma , 2002, Thorax.

[29]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.

[30]  J. Palca.  Nicotine addiction , 1988, Nature.